NCT04444726

Brief Summary

this study is conducted to compare the effect of phototherapy" psoralen plus UVA " bath puva to tap water iontophoresis in the treatment of atopic dermatitis in children.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 20, 2019

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

June 20, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 23, 2020

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 20, 2020

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 21, 2020

Completed
Last Updated

June 10, 2021

Status Verified

June 1, 2021

Enrollment Period

1.8 years

First QC Date

June 20, 2020

Last Update Submit

June 8, 2021

Conditions

Keywords

Atopic dermatitis, Phototherapy, iontophoresis

Outcome Measures

Primary Outcomes (1)

  • Patient Oriented Eczema Measure" POEM"

    The severity of eczema was estimated by asking young children to complete the questionnaire with the help of their parents. They were asked to leave blank any questions you feel unable to answer.

    8 weeks of treatment

Secondary Outcomes (1)

  • Thickness of the skin " Ultrasonography"

    8 weeks of treatment

Study Arms (3)

Phototherapy "PUVA" +traditional medical treatmentn

EXPERIMENTAL

patient sock his hands in a bath containing water with the constitution of psoralen "meladinine " capsule for 20 minutes then irradiated at the UVA device for 3 sessions per week for 8 weeks Plus the traditional medical treatment. which is the betamethasone dipropionate 0.05% " diprolene for 2 times a day for 8 weeks.

Device: Ultra Violet A Device.+ Topical medical treatmentDrug: Topical medical treatment (Betamethasone dipropionate 0.05% " diprolene " )

Tap Water Iontophoresis + Traditional medical treatment

EXPERIMENTAL

Tap-water iontophoresis was given 3 times weekly for 10 min The direct current level was slowly increased, guided by the occurrence of tingling sensations. The maximum level was 30mA. Plus the traditional medical treatment. which is the betamethasone dipropionate 0.05% " diprolene for 2 times a day for 8 weeks.

Device: Iontophoresis device + Topical medical treatmentDrug: Topical medical treatment (Betamethasone dipropionate 0.05% " diprolene " )

traditional medical treatment

ACTIVE COMPARATOR

Traditional medical treatment. which is the betamethasone dipropionate 0.05% " diprolene for 2 times a day for 8 weeks.

Drug: Topical medical treatment (Betamethasone dipropionate 0.05% " diprolene " )

Interventions

Hands of the patient are irradiated in the UVA device after soaking for 20 minutes into 10 litres of water containing psoralen "meladenine capsule".

Phototherapy "PUVA" +traditional medical treatmentn

Tap-water iontophoresis was given 3 times weekly for 10 min. The direct current level was slowly increased, guided by the occurrence of tingling sensations. The maximum level was 30 mA.

Tap Water Iontophoresis + Traditional medical treatment

thin film of the cream is being applied to the affected areas for 2 times per day.

Phototherapy "PUVA" +traditional medical treatmentnTap Water Iontophoresis + Traditional medical treatmenttraditional medical treatment

Eligibility Criteria

Age9 Years - 16 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Age between 9 to 16 years.
  • Suffering from AD of dyshidrotic as well as dry types of more than 6-months duration
  • Traditional types of treatment options, including oral or topical corticosteroids, proved ineffective.

You may not qualify if:

  • Intolerance history to UV radiation.
  • Skin malignancy at the area to be treated.
  • Acute infection at the treated area.
  • Children received radiotherapy in the area to be treated during the last 6 months.
  • Children received corticosteroid therapy topically within 14 days before treatment, or systemic corticosteroids or any immunosuppressive drugs within the last 4 weeks.
  • Circulatory and sensory disorders and children with diabetes mellitus.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Banha University

Banhā, Egypt

Location

MeSH Terms

Conditions

Dermatitis, Atopic

Interventions

betamethasone-17,21-dipropionate

Condition Hierarchy (Ancestors)

Skin Diseases, GeneticGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesDermatitisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, EczematousHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor , department of physical therapy for basic science, Faculty of Physical Therapy , Cairo university.

Study Record Dates

First Submitted

June 20, 2020

First Posted

June 23, 2020

Study Start

January 20, 2019

Primary Completion

November 20, 2020

Study Completion

November 21, 2020

Last Updated

June 10, 2021

Record last verified: 2021-06

Data Sharing

IPD Sharing
Will share

Data will be shared after 6 month of publication .

Shared Documents
ICF, CSR

Locations